Recent moves on the Street have been mostly positive yet varied. In October 2026, Stifel's Jonathan Siegmann lifted his target to $925 with a Buy rating, Cantor Fitzgerald's Colin Canfield raised his to $785 (Overweight), Macquarie started coverage at $780 (Outperform), Goldman Sachs increased its target to $745 (Buy), Jefferies upgraded to Buy with a $725 target, and TD Cowen's Gautam Khanna set $700 (Buy). On the more measured side, Citi's John Godyn placed a $689 target with a Neutral rating, while BNP Paribas Exane moved to a Sell rating.
Averaging the roughly ten attributable targets lands near $760. The spread from roughly $689 to $925 stands out as wide, showing clear differences in how much of CACI's growth and margin upside analysts see as already priced in. The average is simply a mathematical midpoint, not a promise, and it gets pulled higher by a few optimistic estimates.
CACI last traded near $675.62, close to the upper end of its 52-week range of roughly $434.70 to $689.15. Hitting the $760 central target would point to upside of about 12.5% — a measured step for a name that has already posted solid gains over the past year. The trajectory would likely hinge on steady execution against a sizable funded backlog, ongoing margin gains from higher-technology work, and careful capital allocation following the ARKA acquisition.
The shares are trading just below their 52-week high near $689, a zone that has acted as resistance on prior attempts. A decisive break above $689–$690 would clear an important psychological and technical barrier and open room toward the $700 level and eventually the central $760 target. On the downside, the earlier consolidation zone and the $434.70 52-week low frame the longer-term uptrend, which stays intact as long as the stock holds above major moving-average support.
Analyst price targets generally cover a roughly twelve-month horizon, though individual firms may vary. Investors should monitor the next quarterly earnings release, updated fiscal guidance, the pace of contract bookings, and backlog conversion. Additional analyst target changes, federal budget developments, interest-rate decisions, and the integration progress on ARKA stand out as the most relevant markers for whether $760 becomes attainable.
The $760 central target, an average of roughly ten recent analyst price targets, sits about 12.5% above CACI's latest price near $675.62. A robust backlog, improving margins, technology-driven contract wins, and the ARKA acquisition offer a credible base for further gains, while federal funding risk, contract execution challenges, and a demanding valuation remain the main hurdles. The unusually wide target range — from roughly $689 to $925 — highlights that this remains a debated name rather than a settled outcome. Whether the shares reach $760 will depend on continued execution and whether the higher expectations now embedded in the stock are met.
I also checked this using Tickeron's AI Daily Buy/Sell Signals to see how the stock compares to others in the industry. These signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions, technical patterns, and AI-driven analysis. For a name like CACI that can move with defense spending news, having this automated layer alongside traditional research helps spot changes in trend or momentum more efficiently.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CACI declined for three days, in 154 of 256 cases, the price declined further within the following month. The odds of a continued downward trend are 60%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CACI as a result. In 45 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
The Moving Average Convergence Divergence Histogram (MACD) for CACI turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 28 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
CACI moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
CACI broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator entered the oversold zone -- be on the watch for CACI's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for CACI crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where CACI advanced for three days, in 232 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The Aroon Indicator entered an Uptrend today. In 133 of 242 cases where CACI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
The Tickeron Profit vs. Risk Rating rating for this company is 31 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. CACI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.027) is normal, around the industry mean (2.936). P/E Ratio (25.171) is within average values for comparable stocks, (18.739). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (2.331). Dividend Yield (0.000) settles around the average of (0.228) among similar stocks. P/S Ratio (1.463) is also within normal values, averaging (141.748).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of professional services and information technology solutions
Industry InformationTechnologyServices